Cinacalcet hydrochloride, a calcimimetic that binds to the calcium-sensing receptor, has been approved for the long-term control of hypercalcemia secondary to pHPT in individuals who are unable to undergo parathyroidectomy and for the treatment of parathyroid carcinoma-related hypercalcemia, in case of unresectable or metastatic disease. The gene discussed is CASR; the disease is Hypercalcemia.